** Shares in Orpea ORP.PA slump around 30% after it
reached agreement in principle with creditors on its debt
restructuring
** The deal reached with French public lender CDC and other
investors will see the CDC-led group own 50.2% of Orpea with
other unsecured financial creditors holding 49.4% of its capital
following debt-to-equity conversion and subsequent capital
increases
** Current shareholders, if they choose not to participate
in capital increases open to them, will see their stake reduced
to 0.4%
** Apart from stakes dilution, CDC's taking control also
means no hope for the return of high profitability, and the
resumption of dividends at least for the mid-term, AlphaValue's
Yi Zhong says
** "In short it is a disaster for all investors," she adds
** Orpea shares lost around 65% in value over 2022 and
further roughly 22% since the beginning of 2023
** "Korian and other non-listed competitors will be put
under pressure as well," Zhong says
** Peer Korian KORI.PA slips around 1.5%
(Reporting by Lina Golovnya, Diana Mandiá, Piotr Lipinski)
((lina.golovnya@tr.com))